<DOC>
	<DOCNO>NCT02591173</DOCNO>
	<brief_summary>Pharmacologic approach increase level action vasodilatory peptide angiotensin- ( 1-7 ) currently development treatment hypertension base finding animal model . There limited contradictory clinical study , however , clear peptide regulate blood pressure human . The purpose study well understand cardiovascular effect angiotensin- ( 1-7 ) human hypertension , examine interaction peptide autonomic nervous system . The investigator propose difficulty show angiotensin- ( 1-7 ) cardiovascular effect previous clinical study relate buffer capacity baroreceptor reflex prevent change blood pressure . Autonomic failure provide ideal patient population test hypothesis . These patient loss baroreflex buffer low level angiotensin- ( 1-7 ) blood . The investigator test angiotensin- ( 1-7 ) infusion lower blood pressure patient autonomic failure , determine hemodynamic hormonal mechanism involve effect .</brief_summary>
	<brief_title>Blood Pressure Lowering Effects Angiotensin- ( 1-7 ) Primary Autonomic Failure</brief_title>
	<detailed_description>This inpatient study require least four day admission Vanderbilt Clinical Research Center . Autonomic failure patient place fixed diet admission routine test perform screen clinical characterization . Patients receive intravenous angiotensin- ( 1-7 ) saline infusion two separate study day , study day last approximately 3 hour . There least one washout day study day . Patients instrument two intravenous catheter ( one blood sample one drug infusion ) , arm finger blood pressure cuff , sticky patch measure heart rate study . The investigator take baseline measurement blood pressure heart rate collect blood sample . The investigator also perform rebreathing test measure heart 's pumping capacity . After baseline measurement , investigator infusion angiotensin- ( 1-7 ) saline 50 minute . There five dos angiotensin- ( 1-7 ) . Each dose maintain 10 minute . The investigator measure blood pressure heart rate , repeat rebreathing test , collect blood sample end dose period .</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Pure Autonomic Failure</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Autonomic Nervous System Diseases</mesh_term>
	<mesh_term>Primary Dysautonomias</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>Males female race 18 80 year age . Diagnosed primary autonomic failure supine hypertension . Supine hypertension define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 90 mmHg lying . Able willing provide inform consent . Pregnancy breast feed . Hemoglobin &lt; 10.5 hematocrit &lt; 32 . Highrisk patient ( e.g . heart failure , symptomatic coronary artery disease , liver impairment , renal failure , history stroke myocardial infarction ) . Inability give withdraw inform consent . Other factor investigator 's opinion would prevent patient complete protocol ( e.g . clinically significant abnormality clinical , mental examination , laboratory test inability comply protocol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Autonomic</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Renin-Angiotensin System</keyword>
</DOC>